Top Stories

Audax Private Equity, EQT and NMS Capital are among the PE firms pursuing deals and sales in the clinical trial sector.

'2025 may bring some shifts as we welcome a new administration, potentially influencing areas like trade policies and immigration.'

The surge was propelled by an increase in large deals and greater interest in biopharma and healthcare IT, Nirad Jain said in an exclusive interview with PE Hub.

Epiris' deals in 2024 include the acquisition of Amber Taverns, which operates pubs predominantly in north England.

'Junior capital offers delayed draw capacity, which is a critical source of funding for sponsors with buy-and-build investment strategies seeking to make post-closing acquisitions.'

2024 was a 'very good period for dealmaking' and Sullivan Street hopes this momentum will continue into 2025.

'We focus on growth not cost cuts. This is a win for all parties. It’s liquidity much faster and easier than an IPO. It’s partnership with a growth investor.'

PAI is optimistic about the new year, with eyes on opportunities for companies in the real economy.

Béla Szigethy and Stewart Kohl: 'Investors remain highly discerning, selective and willing to do more work, dig deeper in diligence, be more patient and demanding, and GPs must respond with enhanced fundraising capacity and improved stewardship.'

‘The market has come towards the sellers, but the sellers have also now agreed to reduce their expectations,’ the Bridgepoint chief investment officer told PE Hub in this NEXUS 2025 preview interview.